Skip to main content
RIGL
NASDAQ Life Sciences

Rigel Pharmaceuticals Reports Q1 Revenue Miss, Eli Lilly Terminates Collaboration

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$27.47
Mkt Cap
$519.104M
52W Low
$16.88
52W High
$52.24
52W Position info
63% above low
Off High info
47% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

RIGL sits 63% above its 52-week low of $16.88.

Summary

Rigel Pharmaceuticals announced first-quarter financial results below analyst expectations and a year-over-year decline in net income, compounded by the termination of a collaboration agreement with Eli Lilly for a key pipeline asset.


Key Events · Earnings and Guidance · RIGL

  • Q1 Financial Results Below Estimates

    Rigel reported Q1 2026 total revenues of $58.8 million, falling short of analyst estimates of $62.39 million, and net income of $8.7 million, down from $11.4 million in Q1 2025.

  • Eli Lilly Terminates Collaboration Agreement

    Eli Lilly and Company notified Rigel of the termination of their collaboration agreement for ocadusertib (a RIPK1 inhibitor), effective June 15, 2026, impacting a pipeline asset.

  • Debt Facility Restructured

    The company restructured its credit relationship, replacing an existing term loan with a new $40.0 million revolving credit facility (with an option to increase to $60.0 million), repaying the remaining $40.0 million term loan and drawing $8.0 million on the new facility.

  • 2026 Financial Outlook Reaffirmed

    Rigel reaffirmed its full-year 2026 total revenue guidance of $275 million to $290 million and anticipates reporting positive net income for the full year.


Analysis · RIGL · Life Sciences

Rigel's first-quarter results indicate a financial setback with revenues missing analyst expectations and a decline in net income compared to the prior year. More significantly, the termination of the collaboration with Eli Lilly for ocadusertib represents a loss of a pipeline asset and potential future revenue, which is a material negative for a biotechnology company. While the company restructured its debt for increased financial flexibility and reaffirmed its full-year guidance, the immediate impact of the revenue miss and the collaboration termination creates a negative outlook. Investors should monitor the company's ability to meet its reaffirmed guidance and the impact of the collaboration termination on its long-term pipeline strategy.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RIGL was trading at $27.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $519.1M. The 52-week trading range was $16.88 to $52.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RIGL - Latest Insights

RIGL
Nov 05, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $43.90
Real-time Price: $42.53 info
Change: -$1.37 (-3%) info
Market Cap: $800.839M info
RIGL
Nov 05, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.00
Real-time Price: $42.53 info
Change: -$1.47 (-3%) info
Market Cap: $800.839M info
RIGL
Aug 04, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.20
Real-time Price: $42.53 info
Change: +$1.33 (+3%) info
Market Cap: $800.839M info
RIGL
Aug 04, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $39.84
Real-time Price: $42.53 info
Change: +$2.69 (+7%) info
Market Cap: $800.839M info
RIGL
Jul 01, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.29
Real-time Price: $42.53 info
Change: +$4.24 (+11%) info
Market Cap: $800.839M info